Dr. Eric A. Ortlund's lab focuses on understanding and targeting a specific protein, LRH-1, which plays a key role in managing how our bodies process fats and sugars. By developing new small molecules that can activate LRH-1, the lab aims to find therapeutic solutions for diseases linked to obesity, like diabetes and fatty liver disease. They also create innovative mouse models to test these new treatments more effectively.

Dr. Neil Osheroff's lab at Vanderbilt University focuses on understanding how certain antibiotics work and how bacteria resist them. The lab studies key bacterial enzymes that are targets for widely used antibacterial drugs like fluoroquinolones. By investigating these enzymes and their interactions with both existing and novel antibiotics, the team aims to develop new strategies to combat antibiotic-resistant bacterial infections.

Dr. James A. Imlay's lab studies how bacteria cope with the challenges posed by oxygen and reactive oxygen species. Bacteria have evolved various defenses to counteract the damaging effects of oxidative stress that can harm their enzymes and DNA. By investigating how different bacteria produce and manage reactive oxygen species, the lab aims to enhance our understanding of bacterial survival and adaptation in oxygen-rich environments, potentially leading to better antibiotic development.

Dr. Tao Pan's lab at the University of Chicago focuses on understanding small nucleolar RNAs (snoRNAs), which are important molecules that help guide modifications in ribosomal RNA and can influence gene expression. By using advanced sequencing technologies, the lab aims to uncover the roles and interactions of these snoRNAs in human cells and how they impact various biological processes and diseases. This work could provide new insights into genome regulation and RNA-based therapies.

Dr. Alan D Attie's research lab focuses on uncovering the genetic and cellular mechanisms behind type 2 diabetes, particularly the roles of pancreatic islet cells in insulin regulation. They use a diverse mouse population to identify new genes and small molecules that influence insulin secretion and ultimately impact blood sugar levels. Their work aims to offer insights into potential therapies to improve pancreatic function and prevent diabetes progression.

Dr. Christopher J Lyon's lab focuses on improving the diagnosis and management of tuberculosis (TB) in children, particularly those under five years old. The lab is developing a novel blood-based assay that detects proteins from the TB pathogen and the host's immune response using advanced immunoassay technology. By leveraging accessible diagnostic methods, the research aims to enhance the sensitivity and accuracy of TB detection in pediatric patients, especially in resource-limited settings.

Dr. Christopher C. W. Hughes leads a research lab that focuses on developing advanced models for studying a form of cancer known as peritoneal carcinomatosis, particularly as it relates to colorectal and gastric cancers. The lab aims to create a microfluidic system that closely mimics human tissues to better understand tumor behavior and discover new treatments. Ultimately, their efforts will contribute to improved therapies for patients suffering from these aggressive cancers, addressing significant health disparities related to treatment outcomes.

Dr. Margaret A. Phillips leads a research lab focused on developing new drugs to combat malaria, particularly in light of increasing drug resistance. Her team aims to optimize DHODH inhibitors, which can target a specific enzyme crucial for the malaria parasite's survival, using both computational models and experimental techniques. The goal is to identify safer and more effective compounds that are less likely to lead to drug resistance, thus improving treatment options for this life-threatening disease.

Dr. Donald G. Phinney's lab focuses on improving the therapeutic applications of mesenchymal stem cells (MSCs) for various human diseases. By developing a Clinical Indications Prediction (CLIP) scale, the lab aims to enhance the understanding of how donor characteristics and manufacturing processes affect the potency of MSCs. This research is crucial in creating tailored MSC therapies that yield better patient outcomes.

Dr. Visvanathan Ramamurthy's lab focuses on developing therapies for vision loss caused by defects in photoreceptor outer segments. These segments are critical for our ability to see, and when they don't develop correctly, it can lead to blindness. The lab studies a specific protein called Prominin-1, which has been linked to several eye diseases, and seeks to find ways to treat conditions associated with mutations in this protein.

Dr. Joseph Piccirilli's lab at the University of Chicago focuses on understanding the role and structure of non-coding RNAs and their complexes with proteins and small molecules. They utilize innovative chemical and biochemical methods to investigate how these RNAs function in health and disease. By developing synthetic antibodies and studying catalytic RNAs, the lab aims to reveal critical insights into RNA structures and their biological significance.

Dr. Melissa Harrison's lab at the University of Wisconsin-Madison focuses on how certain transcription factors, known as pioneer factors, can reprogram the genetic material in early embryos to enable development. By studying the molecular mechanisms that these factors use to bind to DNA and modify gene expression, the lab aims to uncover fundamental processes that impact growth and health. This research has implications for understanding both normal development and diseases related to gene regulation.

Dr. Wolfgang Bergmeier's lab at the University of North Carolina focuses on understanding how certain cellular signaling pathways influence the behavior of platelets, which are crucial for blood clotting. The research seeks to unravel the mechanisms that lead to problems like excessive bleeding or unwanted blood clots in conditions such as cancer and thrombosis. By identifying how platelets function and their role in blood diseases, the lab aims to develop better diagnostics and treatments for these critical health issues.

Dr. Kathrin Plath's lab focuses on understanding how gene expression is regulated on the X chromosomes during embryonic development and its crucial role in the placenta's function. They specifically study X chromosome dosage compensation mechanisms and how their disruption can lead to developmental issues in embryos. By using mouse models, the lab aims to uncover the underlying processes affecting the feto-maternal interface, ultimately providing insights into female-specific developmental disorders and placental health.

Dr. Richard T. Pomerantz leads a research lab at Thomas Jefferson University focused on DNA repair mechanisms, specifically those involving double-strand breaks and their implications in cancer therapy. His team's work includes developing targeted drugs for BRCA-deficient cancers and new treatments for diffuse large B-cell lymphoma (DLBCL). They utilize innovative strategies to improve existing therapies and explore previously unrecognized DNA repair pathways.

Dr. Daniel Portnoy's lab at UC Berkeley studies how certain bacteria, like Listeria and Mycobacterium tuberculosis, evade our immune systems. They focus on understanding both the bacteria's tricks to cause disease and the body's responses to them. This research aims to develop better vaccines and treatments for bacterial infections by leveraging insights into the interactions between bacteria and immune responses.

Dr. Surachai Supattapone's lab at Dartmouth College focuses on understanding prion diseases, which are caused by misfolded proteins that lead to neurodegenerative disorders such as Creutzfeldt-Jakob disease. The lab uses advanced genetic screening techniques to map the molecular pathways that control the metabolism of prion proteins, aiming to identify potential new targets for drug therapy. Their research not only enhances our knowledge of prion biology but also contributes to the development of therapeutic strategies for these fatal brain diseases.

David A Harris's lab at Boston University Medical Campus focuses on understanding the mechanisms behind inherited prion diseases—neurodegenerative disorders caused by misfolded proteins. By using advanced techniques like induced pluripotent stem cells (iPSCs), the lab studies how mutations in prion proteins lead to neuronal damage and other cellular dysfunctions. This research aims to uncover potential therapies not only for prion diseases but also for related conditions such as Alzheimer's disease.

Dr. Lila Gierasch's lab focuses on understanding how proteins fold correctly within cells, particularly through the action of heat shock proteins like Hsp70. These molecular chaperones play a critical role in maintaining protein health by helping them achieve their functional forms and preventing misfolding that can cause diseases like Alzheimer's and Parkinson's. The lab employs various biochemical techniques to study the mechanisms of protein binding and the effects of mutations on these processes, aiming to find new ways to target these proteins for disease intervention.

Farren J. Isaacs' lab at Yale University focuses on understanding how proteins interact with each other and how their functions are modified by chemical changes called post-translational modifications (PTMs). By engineering bacteria to produce proteins with specific modifications, the lab aims to uncover the role of these modifications in crucial cellular processes and disease states. This pioneering work could lead to the development of new therapeutic strategies targeting diseases linked to protein interactions.